Impact of In-Hospital PCSK9 Inhibition on Myocardial Inflammation After Myocardial Infarction
Efthymios Ziogos, Tarek Harb, Ines Valenta, Michael Vavuranakis, Palmer Foran, Marlene S. Williams, Michael J. Blaha, Allison G. Hays, Steven R. Jones, Thomas H. Schindler, Steven P. Schulman, Gary Gerstenblith, Thorsten M. Leucker
Abstract
was linked to increased end-systolic volume at 6 months. These findings suggest that early PCSK9 inhibition reduces post-MI myocardial inflammation and may influence cardiac remodeling in the months following the acute event.
Topics & Concepts
MedicineEvolocumabPCSK9Myocardial infarctionCardiologyInternal medicinePlaceboInflammationAcute coronary syndromePathologyApolipoprotein BLipoproteinCholesterolApolipoprotein A1LDL receptorAlternative medicineLipoproteins and Cardiovascular HealthViral Infections and Immunology ResearchAtherosclerosis and Cardiovascular Diseases